Biblio
Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019.
. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol. 2016.
. Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020.
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.
. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016.
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021.
Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020;4(8):1690-1699.
Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol. 2022:103862.
. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol. 2021:1-16.
.